EU Policies & Directives
-
Social Health Protection
This page explains the forms of support that may be available, how to find information about eligibility, and the EU and international frameworks that guide protection for patients and…
Read More » -
Orphan Drugs
What qualifies as an orphan medicine Under Regulation (EC) No 141/2000, a medicine can qualify for orphan designation if it is intended for a life-threatening or chronically debilitating condition affecting…
Read More » -
Rare Diseases
In the European Union, a disease is considered rare when it affects fewer than 5 in 10,000 people. An estimated 27–36 million people across the EU live with a rare…
Read More » -
Cross-Border Healthcare
Rights and funding Entitlement depends on statutory health insurance coverage and applicable rules. Directive 2011/24/EU applies across the EU and European Economic Area; different arrangements apply to Switzerland and the…
Read More » -
-
Pharmacovigilance
Why continuous safety monitoring matters Medicines are evaluated before they are authorised, but clinical trials cannot identify every possible side effect. Some reactions are rare, develop after prolonged treatment or…
Read More » -
Patient Safety
WHO estimates that around 1 in 10 patients experience harm during healthcare, and that more than half of this harm is preventable. Common risks include medication and diagnostic errors, healthcare-associated…
Read More » -
Blood Safety & Availability
The Thalassaemia International Federation (TIF) advocates for national policies that secure sufficient, safe blood and blood components through regular, voluntary and unpaid donation. This requires sustained investment in coordinated blood…
Read More »